HomeCTSO • NASDAQ
Cytosorbents Corp
$0.84
After Hours:
$0.85
(1.00%)+0.0084
Closed: Dec 23, 4:28:15 PM GMT-5 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$0.92
Day range
$0.81 - $0.92
Year range
$0.70 - $1.82
Market cap
45.72M USD
Avg Volume
160.02K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Sep 2024Y/Y change
Revenue
9.39M6.58%
Operating expense
9.61M-24.74%
Net income
-2.33M74.61%
Net profit margin
-24.8676.17%
Earnings per share
-0.0861.90%
EBITDA
-3.95M41.58%
Effective tax rate
Total assets
Total liabilities
(USD)Sep 2024Y/Y change
Cash and short-term investments
5.69M-31.99%
Total assets
47.80M0.48%
Total liabilities
34.80M19.76%
Total equity
13.00M
Shares outstanding
54.68M
Price to book
3.81
Return on assets
-21.40%
Return on capital
-26.00%
Net change in cash
(USD)Sep 2024Y/Y change
Net income
-2.33M74.61%
Cash from operations
-2.46M52.73%
Cash from investing
-298.35K-15.77%
Cash from financing
-99.03K-115.27%
Net change in cash
-2.77M42.13%
Free cash flow
-1.31M53.63%
About
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey. CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood. The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects. CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. Wikipedia
Founded
1997
Employees
186
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu